{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yu Y"],"funding":["National Natural Science Foundation of China","China Postdoctoral Science Foundation","National Institutes of Health","NIH HHS"],"pagination":["e2307022"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10966566"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(12)"],"pubmed_abstract":["In clinics, hepcidin levels are elevated in various anemia-related conditions, particularly in iron-refractory anemia and in high inflammatory states that suppress iron absorption, which remains an urgent unmet medical need. To identify effective treatment options for various types of iron-refractory anemia, the potential effect of hypoxia and pharmacologically-mimetic drug FG-4592 (Roxadustat) are evaluated, a hypoxia-inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitor, on mouse models of iron-refractory iron-deficiency anemia (IRIDA), anemia of inflammation and 5-fluorouracil-induced chemotherapy-related anemia. The potent protective effects of both hypoxia and FG-4592 on IRIDA as well as other 2 tested mouse cohorts are found. Mechanistically, it is demonstrated that hypoxia or FG"],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pubmed_title":["Activation of Intestinal HIF2α Ameliorates Iron-Refractory Anemia."],"pmcid":["PMC10966566"],"funding_grant_id":["32200961","32200964","R01DK095201","82030003","M642414","32171166","31930057","31970689","32330047","2022M712749"],"pubmed_authors":["Wu Q","Wang F","Lin Z","Liu Y","Li X","Das NK","Min J","Sun S","Shah YM","Su Y","Yue W","Yang S","Yu Y","Zhou J"],"additional_accession":[]},"is_claimable":false,"name":"Activation of Intestinal HIF2α Ameliorates Iron-Refractory Anemia.","description":"In clinics, hepcidin levels are elevated in various anemia-related conditions, particularly in iron-refractory anemia and in high inflammatory states that suppress iron absorption, which remains an urgent unmet medical need. To identify effective treatment options for various types of iron-refractory anemia, the potential effect of hypoxia and pharmacologically-mimetic drug FG-4592 (Roxadustat) are evaluated, a hypoxia-inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitor, on mouse models of iron-refractory iron-deficiency anemia (IRIDA), anemia of inflammation and 5-fluorouracil-induced chemotherapy-related anemia. The potent protective effects of both hypoxia and FG-4592 on IRIDA as well as other 2 tested mouse cohorts are found. Mechanistically, it is demonstrated that hypoxia or FG","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2025-04-25T21:33:49.445Z","creation":"2025-04-06T08:48:24.207Z"},"accession":"S-EPMC10966566","cross_references":{"pubmed":["38243847"],"doi":["10.1002/advs.202307022"]}}